儿童造血干细胞移植后胸膜肺弹力纤维增生症:倾向性评分匹配分析
单中心回顾性病例对照研究纳入738例儿童造血干细胞移植后行胸部CT的患者,PPFE发生率为4%(31/738),中位发生时间2.7年。倾向性评分匹配后分析显示,移植后3个月以上肺炎是PPFE的显著危险因素(HR=10.78,95%CI 4.29–27.13,p<0.001),PPFE组死亡率高达73%,中位总生存期6.8年。结论认为PPFE是HSCT后严重类型的晚发性非感染性肺部并发症。
要点
- 儿童HSCT后PPFE发生率为4%,可发生于异基因或自体移植后。
- 移植后3个月以上肺炎显著增加PPFE风险(HR=10.78)。
- PPFE组死亡率73%,中位生存6.8年,预后差。
核心结论
- PPFE是儿童HSCT后一种严重类型的晚发性非感染性肺部并发症,发生率4%,死亡率高,移植后肺炎增加其风险。
研究设计与样本
- 单中心回顾性病例对照研究,纳入738例连续接受胸部CT检查(HSCT后3个月以上)的儿童HSCT受者。
- 采用倾向性评分匹配(4个协变量:年龄、性别、HSCT类型、原发病),匹配后PPFE组30例、对照组130例。
- 使用Fine和Gray回归模型及分层log-rank检验分析危险因素和临床结局。
关键影像表现/征象
- PPFE诊断基于胸部CT表现,具体影像征象原文未详细描述。
- PPFE组更常见晚发性非感染性肺部并发症(LONIPCs)和HSCT后3个月以上肺炎(p<0.05)。
诊断标准与关键数值
- PPFE诊断标准为满足PPFE诊断标准的患者,具体标准原文未列出。
- 多变量分析显示HSCT后3个月以上肺炎的PPFE风险比HR=10.78(95%CI 4.29–27.13),p<0.001。
- PPFE组死亡率73%(22/30),中位总生存期6.8年(95%CI 4.1–9.5),对照组生存优于PPFE组(p<0.001)。
临床应用与阅片要点
- 儿童HSCT后随访胸部CT时,应警惕PPFE的发生,尤其是有移植后肺炎病史的患者。
- CT提示PPFE表现时,不建议行肺活检,因可能引起难治性气胸且无助于诊断。
- PPFE患者预后差,需密切监测和积极管理。
局限性
- 单中心回顾性研究,样本量有限(PPFE组31例),可能存在选择偏倚。
- PPFE诊断标准的具体内容未在摘要中详细说明。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: To investigate the incidence, risk factors, and clinical outcomes of pleuroparenchymal fibroelastosis (PPFE) in pediatric hematopoietic stem cell transplantation (HSCT) recipients.
METHODS: This single-center, retrospective, case-control study included 738 consecutive patients who underwent chest CT more than 3 months after HSCT. We identified patients who fulfilled the diagnostic criteria for PPFE and assessed their clinical characteristics and radiologic findings. Propensity score-matched analysis was performed using four covariates (age, sex, HSCT type, and primary disease). The risk factors and clinical outcomes of PPFE were analyzed using the Fine and Gray regression model and stratified log-rank test in the matched groups.
RESULTS: PPFE was identified in 4% (31/738, 8.3 ± 3.1 years, 15 males) of the pediatric HSCT recipients with a median time of 2.7 years after HSCT, and it occurred following allogeneic (5%, 15/317), autologous (4%, 15/379), or both (2%, 1/42). Matching yielded 30 and 130 cases in the PPFE and control groups, respectively. The PPFE group showed more frequent late-onset noninfectious pulmonary complications (LONIPCs) and pneumonia more than 3 months after HSCT (p < 0.05). Multivariable analysis showed a significantly higher risk of PPFE in HSCT recipients who had pneumonia more than 3 months after HSCT (hazard ratio = 10.78 [95% confidence interval: 4.29, 27.13], p < 0.001). The PPFE group showed higher mortality (73%, 22/30) and poorer median overall survival (6.8 years [95% confidence interval: 4.1, 9.5]) than the control group (p < 0.001).
CONCLUSIONS: PPFE represents a severe type of LONIPC after HSCT. HSCT recipients with pneumonia after HSCT may have an increased risk of PPFE.
KEY POINTS: • The incidence of pleuroparenchymal fibroelastosis is not negligible (4%), and it can occur after either allogeneic or autologous hematopoietic stem cell transplantation. • Pleuroparenchymal fibroelastosis after hematopoietic stem cell transplantation showed poor outcome with a high mortality rate of 73% and median overall survival of 6.8 years. • After hematopoietic stem cell transplantation, pneumonia may increase the risk of pleuroparenchymal fibroelastosis development in children. • Lung biopsy should not be indicated in patients with pleuroparenchymal fibroelastosis findings on chest CT as it can cause refractory pneumothorax without helping the diagnosis.
引用
- Oh, Lee, Yoo, et al. Pleuroparenchymal fibroelastosis after hematopoietic stem cell transplantation in children: a propensity score-matched analysis. Eur Radiol. 2022. PMID: 36346442. doi:10.1007/s00330-022-09188-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。